Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies

Clinical Microbiology and Infection

Volumn 13, Issue 5, 2007, Pages 497-503

  Timmers, G J ^a   Simoons Smit, A M ^a   Leidekker, M E ^a   Janssen, J J W M ^a   Vandenbroucke Grauls, C M J E ^a   Huijgens, P C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Infection; Neutropenia; Prophylaxis; Quinolones; Resistance; Tolerance

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; AMPHOTERICIN B; ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CREATININE; FLUCONAZOLE; LEVOFLOXACIN; PHENETICILLIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ALPHA HEMOLYTIC STREPTOCOCCUS; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; OPEN STUDY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

BACTERIA (MICROORGANISMS);

EID: 34147162383     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01684.x     Document Type: Article

References (22)

1. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 1996; 23: 795-805.
2. Reuter S, Kern WV, Sigge A et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40: 1087-1093.
3. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
4. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 1994; 97: 256-264.
5. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490-494.
6. Broun ER, Wheat JL, Kneebone PH et al. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 1994; 38: 576-579.
7. Hidalgo M, Hornedo J, Lumbreras C et al. Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother 1997; 41: 1175-1177.
8. Bow EJ, Mandell LA, Louie TJ et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125: 183-190.
9. Cruciani M, Malena M, Bosco O et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21: 4127-4137.
10. Cullen M, Steven N, Billingham L et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998.
11. Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987.
12. Timmers GJ, Dijstelbloem Y, Simoons-Smit AM et al. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant 2004; 33: 847-853.
13. Razonable RR, Litzow MR, Khaliq Y et al. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469-1474.
14. Neftel KA, Hauser SP, Muller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis 1985; 152: 90-98.
15. Olaison L, Belin L, Hogevik H et al. Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med 1999; 159: 607-615.
16. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
17. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 (suppl 4): S240-S245.
18. Kern WV, Klose K, Jellen-Ritter AS et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118.
19. van Kraaij MG, Dekker AW, Peters E et al. Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 591-592.
20. Rolston KV, Yadegarynia D, Kontoyiannis DP et al. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis 2006; 10: 223-230.
21. Wisplinghoff H, Seifert H, Wenzel RP et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
22. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.